Drinking fermented milk containing Lactobacillus paracasei 431 (IMULUS™) improves immune response against H1N1 and cross-reactive H3N2 viruses after influenza vaccination: A pilot randomized triple-blinded placebo controlled trial

Journal of Functional Foods

Chaowanee Chupeerach¹  Chadamas Promkam²  Kemika Praengam³  Kobporn Boonnak⁴  Chalat Santivarangkna⁵  Lilly Pathomyok⁵  Dunyaporn Trachootham⁵  Siriporn Tuntipopipat⁵ 

[1] Corresponding authors at: Institute of Nutrition, Mahidol University, 999 Phutthamonthon Sai 4 Road, Salaya, Nakhon Pathom 73170, Thailand.;Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand;Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand;Department of Medicine, Golden Jubilee Medical Center, Mahidol University, Nakhon Pathom 73170, Thailand;Institute of Nutrition, Mahidol University, Nakhon Pathom 73170, Thailand;

关键词: Immune response;    Influenza;    Milk;    Probiotic;    Vaccine;    Lactobacillus casei;   

DOI  :  

来源: DOAJ

【 摘 要 】

A randomized triple-blinded placebo controlled trial was conducted in healthy adults to evaluate the effects of daily consumption of fermented probiotic milk on immune response towards influenza virus type H1N1, H3N2 and Flu-B. Study and placebo groups (n = 30 each) consumed fermented milk containing 109 Lactobacillus casei 431 and acidified milk respectively, and the vaccination was administered two weeks thereafter. The consumption continued for another four weeks. Anti-viral response was tested by Hemagglutination Inhibition (HAI) and ELISA assays. Results showed that study group had higher seroconversion rates for H1N1 and cross-reactive H3N2; higher HAI response (≥2-fold) rates for cross-reactive H3N2 virus; and increased ratios of geometric mean (study/placebo) for HAI titers and IgM of H1N1 and H3N2 viruses following the vaccination. These pilot results indicated that drinking fermented milk may be an approach to raise immune response against influenza A, especially for participants with low pre-existing immune.Clinical Trial Registry: ClinicalTrials.gov NCT02909842

【 授权许可】

Unknown